Showing results (241-250 of 291) with videos related to

Sort By:
Pageof 30
The Oncologist|July 10, 2025
Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinibNaoki Fukuda, Kazuhisa Toda, Tomohiro Chiba, et al.
Scientific Reports|October 16, 2020
Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patientHiroki Osumi, Atsushi Muroi, Mizuho Sakahara, et al.
BMC Cancer|May 30, 2013
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutationAkihiko Miyanaga, Kumi Shimizu, Rintaro Noro, et al.
European Journal of Haematology|January 22, 2013
Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab eraHiroyuki Takahashi, Naoto Tomita, Seiji Sakata, et al.
Cancer Research|July 3, 2008
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancerYoung Lim Choi, Kengo Takeuchi, Manabu Soda, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 8, 2019
Risk stratification for lymph node metastasis using Epstein-Barr virus status in submucosal invasive (pT1) gastric cancer without lymphovascular invasion: a multicenter observational studyHiroki Osumi, Hiroshi Kawachi, Katsuyuki Murai, et al.
Acta Medica Okayama|October 27, 2010
Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in JapanHisakazu Nishimori, Shunji Takahashi, Katsuyuki Kiura, et al.
Therapeutic Advances in Medical Oncology|September 15, 2025
Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)Hiroki Osumi, Takeru Wakatsuki, Akira Ooki, et al.
JCI Insight|December 7, 2021
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylationRay Sagawa, Seiji Sakata, Bo Gong, et al.
Blood Advances|May 20, 2026
Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trialShinichi Makita, Junji Koya, Yasuhiro Suzuki, et al.
Pageof 30